Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines-Reference-Cited by-同舟云学术

Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines

Published:2023-08-17 Issue:10 Volume:25 Page:1107-1115
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Gawlik Michał,Zimodro Jakub Michal,Gąsecka Aleksandra^ORCID,Filipiak Krzysztof J.,Szmit Sebastian

Abstract

Abstract Purpose of Review To provide an update on epidemiology, risk factors, and management of cardiac arrhythmias in oncological patients within the context of the new European Society of Cardiology 2022 guidelines on cardio-oncology. Recent Findings One of the side effects of different chemotherapeutics is their pro-arrhythmic activity. Both atrial and ventricular arrhythmias may be induced by cancer itself or by anticancer treatment. Recent studies report on the cardiotoxic activity of such promising therapies as BRAF and MEK inhibitors, or CAR-T therapy. Summary Risk factors of arrhythmias in oncological patients overlap with cardiovascular diseases risk factors, but there are some groups of anticancer drugs that increase the risk of cardiotoxicity. It is crucial to be aware of the risks associated with the oncological treatment and know how to act in case of cardiotoxicity.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11912-023-01445-x.pdf

Reference43 articles.

1. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019;30(5):781–7. https://doi.org/10.1093/annonc/mdz051.

2. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37(42):3232–45. https://doi.org/10.1093/eurheartj/ehw334.

3. Lee DH, Chandrashekhar S, Fradley MG. Electrophysiologic complications in cancer patients. Methodist Debakey Cardiovasc J. 2019;15(4):282–8. https://doi.org/10.14797/mdcj-15-4-282.

4. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. https://doi.org/10.1093/eurheartj/ehac244.

5. Yun JP, Choi EK, Han KD, et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC CardioOncol. 2021;3(2):221–32. https://doi.org/10.1016/j.jaccao.2021.03.006. This nationwide study shows that although all cancer patients have a higher risk of developing AF, the incidence is varied among different cancer types.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arrhythmias in oncological patients: a compact overview for the clinician;Herzschrittmachertherapie + Elektrophysiologie;2024-08-11

2. Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database;Journal of Infection;2024-08

3. Characteristics of patients with newly diagnosed hematological malignancies referred for echocardiography;Frontiers in Oncology;2024-01-24

4. Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy;Life;2023-10-23